Jewim Pharmaceutical (Shandong) Co., Ltd

Main purpose: According to the relevant provisions of bioequivalence test, the fluticasone propionate suspension for nebulized inhalation produced by GlaxoSmithKline Australia Pty Ltd. (specification: 2ml: 0.5mg) was selected as the reference preparation. The test preparation fluticasone propionate suspension for nebulized inhalation (specification: 2ml: 0.5mg) produced and provided by Shandong Jingwei Pharmaceutical Co., Ltd. was subjected to a preliminary human bioequivalence test under fasting conditions. The pharmacokinetic behavior of the two preparations in healthy Chinese volunteers was compared to evaluate the possibility of bioequivalence of the two preparations under fasting conditions. Secondary purpose: Observe the safety of oral inhalation of the test preparation fluticasone propionate suspension for nebulized inhalation (specification: 2ml: 0.5mg) and the reference preparation fluticasone propionate suspension for nebulized inhalation (specification: 2ml: 0.5mg) in healthy subjects.

The main purpose of the study was to investigate the pharmacokinetics of beclomethasone formoterol inhalation aerosol (test preparation, 120 presses per bottle, each press contains 100μg beclomethasone dipropionate and 6μg formoterol fumarate) produced by Shandong Jingwei Pharmaceutical Co., Ltd. and beclomethasone formoterol inhalation aerosol (reference preparation, trade name: Qierchang®, 120 presses per bottle, each press contains 100μg beclomethasone dipropionate and 6μg formoterol fumarate) certified by Chiesi Farmaceutici SPA in healthy subjects after fasting administration, and to evaluate the bioequivalence of the two preparations. The secondary purpose of the study was to observe the safety of the test preparation beclomethasone formoterol inhalation aerosol and the reference preparation (Qierchang®) in healthy subjects.

To compare the differences in absorption extent and rate of Entacapone Bidopa Tablets (II) (Specifications: 100 mg levodopa, 25 mg carbidopa, and 200 mg entacapone) produced by Shandong Jingwei Pharmaceutical Co., Ltd. and Entacapone Bidopa Tablets (II) (Specifications: 100 mg levodopa, 25 mg carbidopa, and 200 mg entacapone, trade name: Stalevo ®/Dalingfu ®) produced by Orion Corporation in healthy Chinese adult participants under fasting conditions, to evaluate the bioequivalence of the two oral preparations under fasting conditions, and to evaluate the safety of Entacapone Bidopa Tablets (II) (Specifications: 100 mg levodopa, 25 mg carbidopa, and 200 mg entacapone) produced by Shandong Jingwei Pharmaceutical Co., Ltd.